Table 1.
Baseline demographics, clinical treatment received and outcomes.
| Characteristics | BBC+T | TBI+T |
|---|---|---|
| Total number of patients | 30 | 18 |
| Age (years, mean ± SD) | 57.8 ± 11.6 | 52.3 ± 9.9 |
| SEX, N (%) | ||
| Male | 19 (63.3%) | 12 (66.7%) |
| Female | 11 (36.7%) | 6 (33.3%) |
| SURGICAL INTERVENTION AFTER PROGRESSION | ||
| Stereotactic radiosurgery (SRS) | 3 | 1 |
| 2nd or more surgical resection | 5 | 2 |
| Both craniotomy and SRS as indicated | 5 | 4 |
| TMZ (cycles) | 6.1 ± 5.5*# | 19.3 ± 13.3 |
| BEV infusion (times) | 13.6 ± 12.3 | 25.9 ± 12.1 |
| BEV total amount (mg) | 10,080 ± 9,622 | 23,115 ± 11,867 |
| IRI infusion (times) | 2.4 ± 6.7 | 21.3 ± 12.8 |
| IRI total amount (mg) | 552 ± 1,574 | 5,589 ± 3,486 |
| TTFIELDS THERAPY | ||
| Adjuvant user, N (%) | 12 (40%) | 8 (44.4%) |
| Salvage user, N (%) | 18 (60%) | 10 (55.6%) |
| Duration (days) | 274 ± 309 | 534 ± 430 |
| IDH1 mutant detected** | 0/12 | 2/11 |
| TERT promoter mutation detected** | 6/12 | 1/11 |
| EGFR mutant or amplification detected** | 5/12 | 4/11 |
| OUTCOMES | ||
| OS in months, median (95%CI) | 17.8 (13.3–19.9) | 32.5 (17.0–49.0)Ω |
| PFS in months, median (95%CI) | 5.1 (3.3–6.1) | 6.6 (3.7–9.2)Ω |
| OS-R in months, median (95%CI) | 11.8 (8.6–15.8) | 18.9 (10.7–25.3) |
| PFS-R in months, median (95%CI) | 4.7 (3.6–6.3) | 10.7 (6.7–20.8)Ω |
SD, standard deviation; IDH, isocitrate dehydrogenase; TERT, telomerase reverse transcriptase; EGFR, epidermal growth factor receptor. In BBC+T group,
*
four patients never received maintenance TMZ due to severe myelosuppression during the 6-weeks CCRT period;
#
One patient received just 1 maintenance TMZ cycle before switching to another regimen that patient and his family had chosen.
**
11 and 12 cases from TBI+T and BBC+T groups, respectively, had next generation sequencing reports from Foundation Medicine. CI, confidence interval.
Ω
P < 0.05 in at least one of two types of statistical analysis (P-values are in Figure 2).